The company (stock code 603387) was founded in 2002, is a collection of independent innovation and research and development, large-scale production and professional marketing as one, has many subsidiaries and offices at home and abroad of the medical and health industry chain company. The company was listed on the main board of the Shanghai Stock Exchange in July 2017. it is a domestic company listed on the main board of the POCT field. The company focuses on the R & D, production, sales and service of in vitro diagnostic reagents and instruments for 19 years. The company's main products are cardiac troponin I (cTnI), D-dimer (D-Dimer), N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase isoenzyme / cardiac troponin I / myoglobin triad (CK-MB/cTnI/Myo), highly sensitive cardiac troponin I (cTnI), homocysteine / creatine kinase isoenzyme / cardiac troponin I / myoglobin tetraad, Heart and kidney joint (NT-proBNP/NGAL) and so on. Enterprise honor: enterprise honor Nanjing Enterprise Technology Center, advanced production unit of in vitro diagnosis, key high-tech enterprises of the National Torch Plan, etc.